In vitro activity: Anlotinib (formerly known as AL3818) is a novel and potent multi-kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFRα/β, c-Kit, and Ret. Anlotinib as a receptor tyrosine kinase (RTK) inhibitor has potential antineoplastic and anti-angiogenic activities. Anlotinib significantly reduces AN3CA cell number in vitro, characterized by high expression of a mutated FGFR2 protein. Daily oral administration of Anlotinib (5 mg/kg) resulted in a complete response in 55% of animals treated and in a reduced tumor volume, as well as decreased tumor weights of AN3CA tumors by 94% and 96%, respectively, following a 29-day treatment cycle. Whereas carboplatin and paclitaxel failed to alter tumor growth, the combination with Anlotinib did not seem to exhibit a superior effect when compared with Anlotinib treatment alone.

Kinase Assay: Anlotinib (formerly known as AL3818) is a novel and potent multi-kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFRα/β, c-Kit, and Ret.

Cell Assay: AL3818 significantly reduces AN3CA cell number in vitro, characterized by high expression of a mutated FGFR2 protein. Daily oral administration of AL3818 (5 mg/kg) resulted in a complete response in 55% of animals treated and in a reduced tumor volume, as well as decreased tumor weights of AN3CA tumors by 94% and 96%, respectively, following a 29-day treatment cycle. Whereas carboplatin and paclitaxel failed to alter tumor growth, the combination with AL3818 did not seem to exhibit a superior effect when compared with AL3818 treatment alone.